Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 31, 2008

Sequenom MassARRAY Platform to Be Used in Commercializing Two More SensiGen Tests

  • Sequenom will exclusively supply platform technology and reagents to commercialize SensiGen’s chronic kidney disease and lupus tests. The companies previously allied to commercialize SensiGen’s HPV test on Sequenom’s MassARRAY platform.

    The expanded agreement also gives Sequenom a future right to a minority equity interest in SensiGen.